Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Overview of attention for article published in The Lancet, November 2012

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 74 news outlets
blogs: 4 blogs
policy: 3 policy sources
twitter: 20 X users

patent: 3 patents
facebook: 2 Facebook pages
wikipedia: 6 Wikipedia pages
googleplus: 1 Google+ user

Citations

dimensions_citation: 1017 Dimensions

Readers on

mendeley: 770 Mendeley

Summary News Blogs Policy documents X Patents Facebook Wikipedia Google+ Dimensions citations

So far, Altmetric has seen 12 policy documents that reference this research output.

Ozanimod for treating relapsing–remitting multiple sclerosis : Final appraisal determination committee papers

Cited by National Institute for Health and Care Excellence on 05 May 2021

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis Optica Spektrum und MOG-IgG-assoziierte Erkrankungen - Living Guideline: Langfassung der Leitlinie "Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis Optica Spektrum und MOG-IgG-assoziierte Erkrankungen - Living Guideline"

Cited by The Association of the Scientific Medical Societies in Germany on 17 Feb 2021

The Association of the Scientific Medical Societies in Germany (AWMF) is an umbrella organization of over 150 societies, and advises the government of the Federal Republic of Germany as well as the governments of the German federal countries in all topics of scientific medicine and medical research and classification.

Ozanimod for treating relapsing–remitting multiple sclerosis : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 22 Jan 2021

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis : Committee papers

Cited by National Institute for Health and Care Excellence on 15 Jan 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity, including 8 additional policy documents.